The U.S. Food and Drug Administration has classified a nationwide recall of nearly 3,800 bottles of a combination blood pressure medication after testing found that the pills failed to dissolve properly.

Macleods Pharma USA, based in New Jersey, is recalling certain lots of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets. The recall was initiated on October 7 and classified by the FDA as a Class II recall on October 26.

The recall affects 3,528 bottles containing 30 tablets from lot 12251163A and 216 bottles containing 90 tablets from lot 12251163B. Both lots have an expiration date of May 31, 2027.

The FDA cited “failed dissolution specifications” as the reason for the recall. This means the tablets did not dissolve as required during quality testing, potentially affecting how the medication is released and works in the body.

A Class II recall means use of the affected medication may cause temporary or medically reversible health consequences. The likelihood of serious health consequences is considered remote.

Anyone taking this medication should check the lot number on their prescription bottle to determine whether it is included in the recall. Patients who have an affected product should contact their pharmacist or prescribing healthcare provider for guidance before making changes to their medication.

The recall follows other recent action involving blood pressure medication. In September, the FDA classified a separate recall of 13,567 bottles of chlorthalidone tablets after those pills also failed dissolution testing.

This article was independently written by the BJL Newsroom based on reporting from WBAL-TV and information published by the U.S. Food and Drug Administration.